Remove CMS Remove Heart Transplant Remove Medicare
article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. We are pleased that CMS has provided coverage support for the confirmatory CardiAMP Heart Failure II study.” said Peter Altman , PhD.,

CMS 111
article thumbnail

Procyrion Announces First Patient Enrollments in the DRAIN-HF Pivotal IDE Trial for Aortix Percutaneous Mechanical Circulatory Support Technology

DAIC

The study also includes a registry for advanced heart failure patients who are end stage and not considered to be surgical candidates for a heart transplant or left ventricular assist device (LVAD) implant due to excessive fluid retention and poor kidney function.